Cystinosis News and Research

Latest Cystinosis News and Research

Raptor Pharmaceutical appoints Llew Keltner to its board of directors

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), today announced the appointment of Llew Keltner, M.D., Ph.D., to the Company's board of directors. Dr. Keltner is currently CEO and President of Light Sciences Oncology, a privately-held biotechnology company developing a late-stage, light-activated therapy for hepatocellular cancer and other solid tumors.

1 Oct 2009

Raptor and TorreyPines Therapeutics announce merger completion

Raptor Pharmaceuticals Corp. ("Raptor") (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX) announced today the completion of their merger.

1 Oct 2009

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has raised an aggregate $5 million of gross proceeds through a private placement of units ("August 2009 Private Placement") and through the exercise of warrants (the "Warrant Exchange") originally issued in connection with its May/June 2008 private placement.

25 Aug 2009

Brain-derived neurotrophic factor may predict schizophrenia relapse

A factor that helps optimize brain formation and function may also provide clues about whether patients suffering with schizophrenia are headed toward relapse, researchers say.

16 Oct 2008

Raptor Pharmaceuticals initiates phase IIa clinical study for Convivia

Raptor Pharmaceuticals Corp. has announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. , has initiated the Company's first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia program.

21 Apr 2008

Powerful new discovery method speeds up gene discovery

Scientists will be able to pinpoint genetic causes of human diseases faster than ever thanks to a powerful new discovery method unveiled by the Southwest Foundation for Biomedical Research (SFBR) and an international team of researchers.

17 Sep 2007

Promising treatment for Huntington's disease soon to be tested clinically

At the Institut Curie, CNRS and Inserm researchers have shown that cysteamine, which is already used to treat a rare disease called cystinosis, prevents the death of neurons in Huntington's disease. Like Alzheimer's and Parkinson's, Huntington's disease, is characterized by the abnormal death of neurons.

19 Apr 2006

Changes in the names of medicines, healthcare professionals to be vigilant against medication errors

Healthcare professionals should be aware that alphabetised lists of medicines may have changed and should be careful when selecting medicines to avoid medication errors.

30 Apr 2004